BCD-263

DRUG2 trials

Sponsors

Biocad

Conditions

Advanced MelanomaMelanoma (Skin)

Phase 1

A Clinical Study of the Pharmacokinetics and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin

Active, not recruitingNCT06112808

BiocadAdvanced Melanoma

Start: 2023-05-29End: 2027-01-31Target: 300Updated: 2025-07-08

Phase 3

Clinical Study of the Efficacy and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin

Active, not recruitingNCT06640530

BiocadAdvanced Melanoma, Melanoma (Skin)

Start: 2024-03-21End: 2027-03-31Target: 392Updated: 2025-07-08